No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
300529 Jafron Biomedical
- 29.33
- +0.69+2.41%
Post Market May 9 15:00 CST
23.69BMarket Cap45.12P/E (TTM)
29.73High28.53Low105.12KlotVolume28.64Open28.64Pre Close307.68MTurnover2.02%Turnover Ratio54.21P/E (Static)807.56MShares29.7352wk High7.62P/B15.29BFloat Cap15.8852wk Low34.37Limit Up521.33MShs Float101.43Historical High22.91Limit Down4.19%Amplitude3.51Historical Low0.67Dividend TTM29.27Avg Price44.33KlotAsk2.28%Div YieldTTM100Lot Size56.66KlotBid
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
There May Be Reason For Hope In Jafron BiomedicalLtd's (SZSE:300529) Disappointing Earnings
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) stock was strong despite it releasing a soft earnings report last week. However, we think the company is showing some signs that things are more promising t
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 42.3x Jafron Biomedical Co.,Ltd. (SZSE:300529) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E rati
Jianfan Biotech (300529.SZ): Net profit of 285 million yuan in the first quarter increased by 44.90% year-on-year
Gelonghui, April 25, 丨 Jianfan Biotech (300529.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 744 million yuan, up 30.00% year on year; net profit attributable to shareholders of listed companies was 285 million yuan, up 44.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 271 million yuan, up 42.74% year on year; basic earnings per share were 0.3512 yuan.
The Recent 12% Gain Must Have Brightened CEO Fan Dong's Week, Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Most Bullish Insider
Key Insights Significant insider control over Jafron BiomedicalLtd implies vested interests in company growth The top 4 shareholders own 51% of the company Ownership research along with analyst f
Jianfan Biotech (300529.SZ) spent about 500 million yuan to complete the repurchase of 3% shares
Jianfan Biotech (300529.SZ) issued an announcement. As of April 3, 2024, the company has approved a special repurchase certificate...
Jianfan Biotech (300529.SZ): It has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places
Gelonghui March 15 丨 Jianfan Biotech (300529.SZ) said on the investor interactive platform that the company has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places.
Comments
The EPS decline has disappointed the market, leaving investors hesitant to buy. Shareholders face a total loss of 3% per year over five years due to the company's poor performance.
Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past Week 1
The trend of decreasing ROCE and revenue despite increased capital deployment is concerning, suggesting the company may be losing its competitive advantage or market share. The stock has remained flat over the last five years, indicating investors are not impressed with these trends.
Suntront Technology's low P/E ratio is due to its declining medium-term earnings and the market's growth expectations. Investors think the potential for earnings improvement doesn't justify a higher P/E ratio. If recent earnings trends persist, the share price may not fluctuate significantly soon.
Despite a recent earnings dip, Jafron Biomedical's high P/E ratio is justified by its promising earnings outlook. Investors anticipate robust future growth, outweighing any potential earnings deterioration.
Concerns mount as Jafron BiomedicalLtd's returns shrink amidst rising capital investments. The stagnant sales and ineffective growth reinvestment may result in market share loss. Time to seek other investment opportunities?
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg